



# living insights

SEPTEMBER 2014 • ISSUE 3

Published on an occasional basis, *Living Insights* is a source of up-to-date information for followers of the leading Australasian biotechnology company Living Cell Technologies (LCT)

In this edition

- ▶ Meet the chief executive
- ▶ Upcoming annual general meeting
- ▶ Recent conferences and presentations
- ▶ New website and recent announcements

## Meet the chief executive

**Dr Ken Taylor joined Living Cell Technologies in February this year and became chief executive in July.**


**Find out a little more about what makes him tick...**

### What attracted you to Living Cell Technologies?

*I had heard of the work LCT was doing with NTCELL, the most promising candidate for the first ever disease-modifying treatment of Parkinson's disease. Also the reputations of the research scientists and clinical trial experts involved made me very interested in being part of that work.*

### What do you see as the biggest challenges for the company?

*Increasing shareholder value by successfully completing the clinical development of NTCELL is our main priority. I'm also focused on optimising LCT's investment in DIABECCELL through Diatranz Otsuka Limited, our joint venture with Otsuka Pharmaceutical Factory.*



### What do you see as the biggest opportunities for the company?

*We really are at the cutting edge of research in treatments for neurodegenerative diseases. There is potential for LCT to become a world leader in cell therapy for neurodegenerative diseases.*

### What do you think you bring to this role?

*I have 40 years' experience of pharmaceutical research and development in Parkinson's and other central nervous system diseases. I've also got 25 years' experience as a CEO in managing research-based pharmaceutical and biotechnology companies in New Zealand, Australia, the United Kingdom and the United States.*

*Continued on next page*

## Recent conferences and presentations

In August chief executive Dr Ken Taylor attended the **Movement Disorder Society of Australia Conference** in Queenstown where colleagues and peers from around the globe met to discuss current research in treatments for disorders including Parkinson's and Huntington's diseases. Ken met with a number of valuable contacts in the field whose expertise and counsel will be instrumental in increasing the reach of our networks as we work towards commercialisation of NTCELL®.

## Recent publications from our scientists include:

Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand by Wynyard S, Nathu D, Garkavenko O, Denner J, Elliott R.

▶ [Read the abstract here](#)

## Annual General Meeting

Our annual report is currently in production and will be with shareholders ahead of our annual general meeting in Auckland.

We hope to see many of you on

**Tuesday 18 November 2014 at the Novotel Ellerslie  
72-112 Greenlane East, Auckland, New Zealand at 2pm local time.**

If you can't be at the meeting check the LCT website for the chairman's and CEO's presentations which will be posted after the meeting closes.

## Meet the chief executive

CONTINUED

### What would you like to do more of?

*I hope we can get our innovative products to the market to treat diseases with high unmet clinical needs.*

### What would like to do less of?

*Listen to the negative opinions about why truly great New Zealand science cannot be translated to medical products.*

### You came on board as NTCELL program director and now you're CEO. Why is that appropriate?

*To effectively succeed in medical product development you have to manage the whole process from research to market entry. I have the qualifications and a track record of doing that.*


### How does this role differ from anything you've done previously?

*Not much, to be honest. The only difference is that the product is a living cell for transplantation not a pharmaceutical product. But the process is the same: Give the product what it deserves and let the product results lead you to its eventual place in the market.*

*Being listed on the ASX requires that we keep our investors well informed as we head toward commercialising our unique treatments.*

### When you're not thinking about NTCELL, what do you like to do in your spare time?

*Spend time with my family, play golf and tennis and watch the All Blacks.*



## New website

LCT has a new look online. The redesigned LCT website [www.lctglobal.com](http://www.lctglobal.com) went live in May this year. Joint venture company Diatrans Otsuka Limited also has its own dedicated website at [www.dolglobal.com](http://www.dolglobal.com). Take a look and let us know what you think.

▶ You can find all our announcements on our new website here

▶ Or you can follow our updates on Twitter @LCTglobal

LCT is incorporated in Australia with its operations based in New Zealand.

### Australia

Phone: +61 2 9239 0277

Email: [info@lctglobal.com](mailto:info@lctglobal.com)

### New Zealand

Phone: +64 9 276 2690

Email: [info@lctglobal.com](mailto:info@lctglobal.com)

### Media & investor enquiries

Rachael Joel, Botica Butler Raudon

Phone: +64 9 303 3862

Email: [rachaelj@botica.co.nz](mailto:rachaelj@botica.co.nz)

ASX: LCT OTCQX: LVCLY

For more information visit

[www.lctglobal.com](http://www.lctglobal.com)



### Twitter trends

▶ Follow us @LCTglobal

Are you registered to receive our newsletter? ▶ Register here

**LCT DISCLAIMER:** This document contains general background information about the Company's activities current at the date of 15/09/2014. It is information given in summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This should be considered, with or without professional advice, when deciding if an investment is appropriate.

## RECENT ANNOUNCEMENTS FROM LCT:

### AUGUST

#### Successful second implant of NTCELL for Parkinson's disease

A second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL® for Parkinson's disease.

▶ Read the full announcement here

#### Preliminary final report 30 June 2014

The Preliminary Final Report (Appendix 4E) on the results for the year ended 30 June 2014 is now available.

▶ View the full report here

### JULY

#### Appendix 4C quarterly report

The quarterly cash flow report for the quarter ended 30 June 2014 is now available. The company ended the quarter with a cash balance of \$4,554,000 compared to \$5,765,000 last quarter.

▶ View the full report here

### Dr Ken Taylor appointed chief executive

Dr Ken Taylor has been appointed chief executive of Living Cell Technologies. Ken was appointed NTCELL program director in February and became acting chief executive in April.

▶ Read the full announcement here

### JUNE

#### Parkinson's trial resumes patient recruitment

Living Cell Technologies has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson's disease.

▶ Read the full announcement here

